We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+13.07%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$174M
AUM Growth
+$60M
(+53%)
Cap. Flow
+$42M
Cap. Flow
% of AUM
24.17%
Top 10 Holdings %
Top 10 Hldgs %
68.58%
Holding
37
New
14
Increased
5
Reduced
10
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanda Pharmaceuticals
VNDA
|
+$23.7M |
| 2 |
Ligand Pharmaceuticals
LGND
|
+$18.2M |
| 3 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$8.85M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$5.46M |
| 5 |
XOMA
Xoma
XOMA
|
+$3.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BSTC
BioSpecifics Technologies Corp.
BSTC
|
+$13.2M |
| 2 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$11.2M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$2.77M |
| 4 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$2.11M |
| 5 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$1.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
DiaMedica Therapeutics
DMAC
$358M
| $1.14M | 0.65% |
+250,000
| New | +$902K |
|
27
Xenon Pharmaceuticals
XENE
$6.28B
| $1M | 0.58% |
+98,860
| New | +$838K |
|
|
SBBP
28
DELISTED
Strongbridge Biopharma plc.
SBBP
| $932K | 0.54% |
+187,074
| New | +$921K |
|
29
Collegium Pharmaceutical
COLL
$1.16B
| $909K | 0.52% |
+60,045
| New | +$962K |
|
30
Alphatec Holdings
ATEC
$1.43B
| – | – |
-338,278
| Closed | -$775K |
|
|
ATXS
31
DELISTED
Astria Therapeutics
ATXS
| – | – |
-6,948
| Closed | -$182K |
|
|
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
| – | – |
-7,647
| Closed | -$463K |
|
|
BSTC
33
DELISTED
BioSpecifics Technologies Corp.
BSTC
| – | – |
-217,395
| Closed | -$13.2M |
|
|
CORV
34
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| – | – |
-424,101
| Closed | -$1.06M |
|
|
NVLN
35
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| – | – |
-531,662
| Closed | -$447K |
|
|
CEMI
36
DELISTED
Chembio diagnostics, Inc.
CEMI
| – | – |
-147,011
| Closed | -$832K |
|
Similar funds
BIA
ER
FDDB
VM
PF
SCM
CWM
EWM
Stonepine Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Stonepine Capital Management held 37 positions worth $174M, up 53% from $114M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Stonepine Capital Management deployed $42M of net new capital in Q1 2019, opening 14 new positions and adding to 5 existing holdings. Its largest new stake was Ligand Pharmaceuticals: 240,450 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was BioDelivery Sciences International, Inc., an estimated $11.2M trimmed.
- Stonepine Capital Management's largest Q1 2019 buy was Ligand Pharmaceuticals: 240,450 shares worth $18.9M.
- Stonepine Capital Management added most to Vanda Pharmaceuticals in Q1 2019, an estimated $23.7M increase.
- Stonepine Capital Management's biggest Q1 2019 reduction was BioDelivery Sciences International, Inc., cutting an estimated $11.2M.
- Stonepine Capital Management fully exited BioSpecifics Technologies Corp. in Q1 2019, selling an estimated $13.2M.
- Stonepine Capital Management's ten largest holdings make up 69% of its $174M portfolio in Q1 2019.
- Stonepine Capital Management opened 14 new positions and closed 7 in Q1 2019.
- Stonepine Capital Management's portfolio value rose 53% quarter-over-quarter to $174M.
Based on Stonepine Capital Management's 13F filing for Q1 2019, filed 14 May 2019.